



Medicines Management Policy

**Structured Administration & Supply Arrangement
(SASA): Syntometrine ®**

This document should be read in conjunction with the [DISCLAIMER](#)

Issuing Authority

Health Service	Women and Newborn Health Service
Address	374 Bagot Road, Subiaco, Western Australia
Contact	6458 2222

Authorisations

Practitioners:	WNHS Registered Midwives
Practice Setting:	Community Midwifery Program (CMP)
Qualification:	Community Midwifery Program medication competency training
Patients:	Perinatal patient management of mothers and their newborns

Approved Storage Sites

All medicines are approved for storage at the following sites as per the listings on the WNHS Poisons Permit.

Site	Site Address
1.	Suite 13, 11 Wentworth Parade, Success
2.	Shop E05, Lakeside Shopping Centre, Corner Joondalup Drive and Cord St Joondalup WA 6027
3.	Kalamunda Hospital, Elizabeth St, Kalamunda

Syntometrine ® (Oxytocin 5 Units, Ergometrine 500 microg)

Route:	Intramuscular	Brand:	Syntometrine®
Form:	Injection	Strength:	per 1 mL
Dose:	1mL	Quantity:	Single dose only
Instructions:	Administer as a single dose		
Administration Notes:	Administered with the birth of the baby's shoulder or as soon as possible after birth.		
Patient Inclusion:	<p>Prophylaxis of Primary Postpartum Haemorrhage (PPH) in the context of active management of the third stage of labour where the patient has antenatal and/or intrapartum risk factors at home;</p> <ul style="list-style-type: none"> • Previous PPH • Grand multipara: parity 5 or more • Maternal anaemia • APH • Previous Macrosomic baby ≥ 4.5 kg • Uterine fibroids • Spurious labour or prolonged latent phase of labour • Precipitate or in-coordinate labour • Pyrexia in labour • Prolonged active first stage of labour > 12 hours • Prolonged active 2nd stage > 2 hours • Maternal fatigue or exhaustion (dehydration and ketosis) • Prolonged physiological third stage of labour > 60 minutes • Prolonged actively managed third stage > 30 mins 		
Patient Exclusion:	<p>Severe hypertension, pre-eclampsia or eclampsia</p> <p>Severe disorders of cardiac, hepatic or renal functions</p> <p>Sepsis, Occlusive vascular disease</p>		
Adverse Effects:	<p>Nausea, vomiting, uterine hypertonicity and associated abdominal pain, leg cramps, headache, dizziness and skin rashes.</p> <p>Transient increase in blood pressure or hypotension</p> <p>Transient increase in temperature</p>		
Documentation:	Birth Record - CMP MR 08B		
Clinical	WNHS Obstetrics and Gynaecology Medication Guidelines:		

Guidelines	Syntometrine WNHS: Primary PPH at Home (CMP)
-------------------	---

Syntometrine ® (Oxytocin 5 Units, Ergometrine 500 microg)

Route:	Intramuscular	Brand:	Syntometrine®
Form:	Injection	Strength:	per 1 mL
Dose:	1mL	Quantity:	Up to 2 doses in total
Instructions:	Administer as a single dose		
Administration Notes:	Administered if initial dose of oxytocin dose not manage bleeding following delivery of baby.		
Patient Inclusion:	Persistent bleeding following initial administration of oxytocin or Syntometrine® for pretention of Post-Partum Haemorrhage		
Patient Exclusion:	<ul style="list-style-type: none"> • Severe hypertension, pre-eclampsia or eclampsia • Severe disorders of cardiac, hepatic or renal functions • Sepsis, Occlusive vascular disease 		
Adverse Effects:	<p>Nausea, vomiting, uterine hypertonicity and associated abdominal pain, leg cramps, headache, dizziness and skin rashes.</p> <p>Transient increase in blood pressure or hypotension</p> <p>Transient increase in temperature</p>		
Documentation:	Birth Record - CMP MR 08B		
Clinical Guidelines	<p>WNHS Obstetrics and Gynaecology Medication Guidelines: Syntometrine</p> <p>WNHS: Primary PPH at Home (CMP)</p>		



Related policies, procedures and guidelines

WNHS Clinical Guidelines:

- WNHS: [Administration Checking Procedure by Nursing/Midwifery Staff and students](#)
- WNHS: [Medication Management Framework](#)
- WNHS: [Return & Disposal of Medications](#)

References

1. Australian Medicines Handbook. [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2019 [cited 2019 Jan 7] Available from: <https://amhonline-amh-net-au.kelibresources.health.wa.gov.au>
2. Society of Hospital Pharmacists of Australia. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Jan 7]. Available from: <http://aidh.hcn.com.au.kelibresources.health.wa.gov.au>
3. MIMS Australia. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2019 [cited 2019 Jan 15]. Available from: <https://www.mimsonline-com-au.kelibresources.health.wa.gov.au>
4. Structured Administration and Supply Arrangements, Department of Health. Available at https://ww2.health.wa.gov.au/Articles/S_T/Structured-Administration-and-Supply-Arrangements

Date of Issue	07/05/2019	Date of Expiry	31/04/2021
Document ID	wnhs.sasa.Syntometrine	Version	2.0
Authorising Committee			
Committee	Clinical Governance Committee		
Chairperson	Dr Louise Farrell	Endorsed	4/04/2019
Senior Medical Practitioner			
Name	Dr Meredith Arcus		
Position	Director Clinical Services	Approved	07/05/2019
Executive Director			
Name	Dr Jodi Graham		
Authorised	07/05/2019		
Keywords:	SASA, Administration, Community Midwifery Program, CMP		
Owner:	Chief Pharmacist		
Standards	NSQHS Standards: 1  Governance, 4  Medication Safety,		
<p>Printed or personally saved electronic copies of this document are considered uncontrolled.</p> <p>Access the current version from the WNHS website.</p> <p>For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au</p>			

© Department of Health Western Australia 2019